Literature DB >> 330480

Controlled randomized study comparing amoxycillin and pivmecillinam in adult out-patients presenting with symptoms of acute urinary tract infection.

B Bresky.   

Abstract

A comparative study of amoxycillin and pivmecillinam was performed on 298 out-patients with acute urinary tract infection, receiving either 375 mg amoxycillin three times daily or 400 mg pivmecillinam three times daily. The primary cure rate was 90% in the pivmecillinam group compared to 82% in the amoxycillin group. Resistant enterobacteriaceae emerged in approximately 5% of patients receiving amoxycillin but not after treatment with pivmecillinam. No serious side effects were observed in patients receiving picmecillinam and the tolerance was generally good. Upper gastrointestinal side effects were more frequent in the pivmecillinam group whereas lower gastrointestinal side effects predominated in the amoxycillin group. 200 mg pivmecillinam three times daily compared with 400 mg three times daily showed no differences in cure rate and side effects were lower (11% compared to 19%).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330480     DOI: 10.1093/jac/3.suppl_b.121

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Mecillinam in urinary tract infections and in septicaemia.

Authors:  N Frimodt-Møller; T J Ravn
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Mecillinam versus cephaloridine for the treatment of acute pyelonephritis.

Authors:  B Trollfors; M Jertborn; J Martinell; G Norkrans; G Lidin-Janson
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

3.  A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy.

Authors:  A Bint; D Bullock; D Reeves; P Wilkinson
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  Mecillinam and ampicillin separately or combined in gram-negative septicemia.

Authors:  E Ekwall; A Scheja; S Cronberg; K Ganrot-Norlin; M Jonsson; I Juhlin; G Kahlmeter; A Thorén; K E Thulin; G Tunevall
Journal:  Infection       Date:  1980       Impact factor: 3.553

5.  Pivmecillinam plus pivampicillin in urinary tract infections. A double-blind comparison with pivmecillinam alone in hospitalized patients.

Authors:  E P Saltvedt; R Schøyen
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.